The global viral safety testing market is projected to increase from USD 899.8 million in 2025 to USD 3,736.4 million by 2035, registering a compound annual growth rate (CAGR) of 15.3% during the forecast period, according to Future Market Insights (FMI). The industry is expected to generate an additional USD 2,836.6 million in market value over the decade, supported by expanding biopharmaceutical manufacturing, stringent viral contamination control requirements, and the development of advanced therapeutic products. Increasing demand for comprehensive viral screening across biologics, gene therapies, and cell therapies is creating new opportunities for specialized testing laboratories, contract research organizations, pharmaceutical manufacturers, and biotechnology companies.
Market Background: Biopharmaceutical Expansion Strengthens Viral Safety Requirements
The viral safety testing market is gaining importance as pharmaceutical manufacturers and biotechnology developers expand the production of biologics and advanced therapeutic products. Viral contamination detection has become an essential component of pharmaceutical quality assurance, supporting product safety, manufacturing consistency, and regulatory compliance.
According to FMI, increasing biopharmaceutical manufacturing volumes and stringent requirements imposed by regulatory authorities are among the primary factors supporting market expansion. Pharmaceutical manufacturers must implement comprehensive testing protocols to identify and prevent potential viral contamination throughout manufacturing and product development processes.
The growing development of gene and cell therapies is also creating specialized testing requirements. CAR-T cell therapies and other advanced therapeutic modalities require sophisticated viral screening capabilities to evaluate viral vector safety and maintain product quality.
Another important development is the increasing outsourcing of viral safety testing activities. Pharmaceutical companies are turning to specialized contract testing providers to access technical expertise, advanced laboratory infrastructure, and established testing capabilities without independently developing every specialized testing function.
This shift is strengthening opportunities for contract research organizations and independent testing laboratories across established and emerging pharmaceutical markets.
👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-26754
Segment Analysis: Adventitious Virus Tests Lead Product Demand
FMI’s segmentation analysis identifies adventitious virus tests as the leading product category, accounting for 47.2% of the viral safety testing market. These tests play an important role in detecting unexpected viral contaminants in biopharmaceutical manufacturing processes.
The market is divided into four principal test categories:
- Adventitious virus tests:2% market share, representing the largest test-type segment.
- Antibody production tests:6% market participation.
- Retrovirus tests:3% market participation.
- Specific virus tests:9% market participation.
By application, biopharmaceuticals dominate the industry with an estimated 68.4% share. The segment benefits from increasing biologics production, monoclonal antibody manufacturing, and advanced therapeutic development. Medical industry applications account for 24.7%, while other applications represent 6.9%.
The dominance of biopharmaceutical applications reflects the importance of viral contamination detection in manufacturing operations where product quality and regulatory compliance are essential.
As pharmaceutical developers expand their biologics and advanced therapy portfolios, demand for specialized viral safety testing services is expected to increase.
Regional Outlook: China and India Lead Global Growth
FMI’s country-level forecasts indicate that Asia Pacific represents a significant growth opportunity for the viral safety testing industry, supported by expanding pharmaceutical manufacturing capabilities and increasing adoption of advanced testing technologies.
China is projected to record the highest country-level CAGR at 20.7% between 2025 and 2035. India’s viral safety testing market is expected to expand at 19.1%, reflecting increasing pharmaceutical manufacturing capabilities and quality assurance requirements.
Germany follows with an anticipated CAGR of 17.6%, while Brazil is projected to grow at 16.1%.
Other important country-level projections include:
- United States: 14.5% CAGR
- United Kingdom: 13.0% CAGR
- Japan: 11.5% CAGR
China and India are emerging as important growth markets as domestic pharmaceutical manufacturing expands and international quality standards influence testing requirements.
Germany maintains a significant position within Europe through its established pharmaceutical manufacturing and biotechnology research capabilities. The United States continues to represent an important market due to biotechnology innovation and advanced therapeutic development.
The report estimates the European viral safety testing market at USD 287.4 million in 2025. Germany accounts for 38.7% of regional market share, followed by the United Kingdom at 21.3% and France at 16.8%.
These regional differences highlight the importance of pharmaceutical manufacturing concentration, regulatory frameworks, testing infrastructure, and biotechnology investment in determining market opportunities.
Executive Perspective: Advanced Testing Capabilities Become Strategic Priorities
Proposed FMI research commentary – subject to analyst approval:
“The accelerating development of biologics, gene therapies, and cell-based therapeutics is increasing the importance of comprehensive viral safety testing throughout pharmaceutical manufacturing. As regulatory expectations and product complexity evolve, testing providers with advanced analytical capabilities, specialized technical expertise, and scalable laboratory infrastructure will be increasingly important to pharmaceutical manufacturers and biotechnology developers.”
The market outlook highlights the importance of technological innovation and specialized testing capabilities. Companies operating in this sector must address the growing need for accurate viral detection, efficient testing workflows, and comprehensive regulatory documentation.
Next-generation sequencing, automated analytical systems, and integrated data analytics are emerging as important areas of technological development.
Growth Drivers, Challenges, and Emerging Opportunities
FMI identifies five major factors supporting the expansion of the viral safety testing market.
- Increasing biopharmaceutical manufacturing
Expanding biologics production is generating consistent demand for comprehensive viral screening and quality assurance services across pharmaceutical manufacturing facilities.
- Stringent regulatory compliance
Requirements established by regulatory authorities, including the FDA and EMA, are strengthening demand for validated viral safety testing protocols and documented contamination-control procedures.
- Gene and cell therapy development
Advanced therapeutic products, including CAR-T cell therapies, require specialized viral vector testing and sophisticated contamination detection capabilities.
- Growth of contract testing services
Pharmaceutical companies increasingly outsource specialized testing activities to contract research organizations and independent laboratories to access technical expertise and advanced infrastructure.
- Pharmaceutical manufacturing expansion in emerging markets
Growing pharmaceutical production in Asia Pacific and other emerging markets is creating opportunities for local testing infrastructure, specialized laboratory services, and advanced analytical technologies.
Despite these growth drivers, the market faces challenges associated with high testing costs, complex validation procedures, specialized laboratory infrastructure, and limited availability of qualified technical personnel.
FMI also identifies next-generation sequencing integration, automation, digital analytics, and application-specific testing services as important market trends. These technologies are expected to support more comprehensive viral detection, improve operational consistency, and address the specialized requirements of advanced therapeutic manufacturing.
Future Outlook: Market to Generate USD 2.84 Billion in Additional Value
The viral safety testing market is forecast to expand from USD 899.8 million in 2025 to USD 3,736.4 million by 2035, representing a 15.3% CAGR.
FMI’s forecast identifies two important development periods. Between 2025 and 2030, the market is projected to increase from its baseline valuation through expanding testing infrastructure, regulatory harmonization, and pharmaceutical manufacturing growth.
The subsequent 2030–2035 period is expected to see further expansion through specialized testing services, advanced analytical methodologies, and next-generation viral detection technologies.
The research evaluates the market across test types, applications, and major geographic regions. It also examines country-level growth trajectories, competitive positioning, technological developments, and the commercial factors influencing the adoption of viral safety testing services.
Access the Full Viral Safety Testing Market Report
Pharmaceutical manufacturers, biotechnology companies, contract research organizations, laboratory service providers, healthcare investors, and quality assurance professionals can explore the complete findings in Future Market Insights’ Viral Safety Testing Market Size, Share, Trends and Forecast 2025–2035.
The comprehensive study provides market valuations, test-type segmentation, application-level analysis, regional forecasts, country-specific growth rates, competitive landscape assessments, and insights into emerging technologies and industry opportunities.
Related Reports:
- Progesterone Market – https://www.futuremarketinsights.com/reports/progesterone-market
- Immunomodulator Market – https://www.futuremarketinsights.com/reports/immunomodulator-market
- Sacral Nerve Stimulation Market – https://www.futuremarketinsights.com/reports/sacral-nerve-stimulation-market
About Future Market Insights (FMI)
Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.
For Press & Corporate Inquiries
Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales – sales@futuremarketinsights.com
For Media – Rahul.singh@futuremarketinsights.com
For Web – https://www.futuremarketinsights.com













